Outline Research Education Lectures & Courses Clinical Services & Other Works Clinical Performances
Home page URL http://www.tmd.ac.jp/grad/hema/index.html

Staffs

Title Name Researcher information
Professor MIURA Osamu
Junior Associate Professor YAMAMOTO Masahide
Assistant Professor UMEZAWA Yoshihiro
Graduate Student WATANABE Daisuke
Graduate Student YASUDA Shun'Ichirou
NOGAMI Ayako
To the head of this page.▲

Outline

The Department of Hematology is responsible for clinical services at our University Hospital with treatment of patients with various hematological disorders including leukemias, lymphomas, anemia, and hemorrhagic diseases by chemotherapies, immunotherapies, molecularly-targeted therapies, and hematopoietic cell transplantation. Our department is also responsible for teaching undergraduate students with the lecture course in hematology as well as the clinical clerkship and for training junior and senior residents. Our department is also actively involved, with doctoral course students, in basic and clinical researches aiming to elucidate the molecular and cellular mechanisms involved in pathogenesis of hematological malignancies as well as in acquisition of therapy resistance to develop novel efficient therapies against these diseases.
To the head of this page.▲

Research

1. Elucidation of the molecular mechanisms involved in acquisition of resistance against chemotherapies and molecularly-targeted therapies by leukemic cells from chronic myeloid leukemia, acute myeloid leukemia, and various myeloproliferative neoplasms expressing aberrant tyrosine kinases, including BCR/ABL, FLT3-ITD, and Jak2-V617F, aiming to develop novel therapeutic strategies to overcome the resistance.
2. Research focusing on Myeloproliferative Neoplasms (MPN): Tumorigenesis, Chemo-resistance, new drugs.
3.Signal transduction mechanisms from cytokine/growth factor receptors regulating proliferation, survival, and adhesion of hematopoietic cells including leukemia and lymphoma cells.
4. Molecular analysis of Chronic Myeloid Leukemia (CML): rare variants, chemo-resistance, target therapy.
5. Development of novel CAR-T technology: Chimeric Antigen Receptor T-cell targeting leukemia.

The Department is also actively involved in a variety of clinical studies for treatment of various leukemias, lymphomas, and multiple myeloma.
To the head of this page.▲

Education

The Department of hematology is responsible for teaching basic and clinical hematology to the 3rd and 4th grade students in the integrated hematology course and the hematology and oncology united block course. The Department is also responsible for teaching the 5th and 6th grade students in clinical clerkship to obtain basic knowledge and problem-solving abilities in hematology as well as general internal medicine. The Department is also actively involved in training about 24 junior residents every year to acquire clinical skills in hematology and internal medicine and about 4 senior residents to practice diagnosis and treatment of various hematological disorders and to obtain the certificate for hematology specialist. As a division in the Graduate School of Medical and Dental Sciences, the Department is actively involved in education of 6 to 8 graduate students, who participate in the research projects listed above, to obtain the Ph. D. degree in medicine.
To the head of this page.▲

Lectures & Courses

The major objective of the course is to understand the pathophysiology of blood cells, blood cell-forming organs, and hemostasis to provide a basis for rational diagnosis and treatment of their disorders.
To the head of this page.▲

Clinical Services & Other Works

The Department of Hematology provides diagnosis and treatment for hematological diseases, such as leukemia, malignant lymphoma, anemia, and thrombocythemia, with chemotherapeutics, molecularly-targeted drugs, immunosuppressive agents, and hematopoietic cell trans- plantation.
To the head of this page.▲

Clinical Performances

We provide the highest quality of patient care for a wide spectrum of blood diseases and cancers.
To the head of this page.▲